the aid library

LIST OPTIONS

Filter

3728

Sort by:

Direction:

Download (1697)

View PDF (3547)

Prevention of Disability in Buruli Ulcer: Basic Rehabilitation

Simonet, V. World Health Organization WHO (2008) C_WHO

The guide contains valuable tools for wound care and the rehabilitation of people affected by Buruli ulcer. It is also helpful for peripheral health centres in areas where Buruli ulcer is endemic and to people and their families affected by the disease

Download (1910)

View PDF (5577)

Outbreak Communication

World Health Organization (2005)

Best practices for communicating with the public during an outbreak

Download (548)

View PDF (1775)

WHO recommendations on interventions to improve preterm birth outcomes

World Health Organization WHO (2015) C_WHO

The primary audience for this guideline includes health-care professionals who are responsible for developing national and local health-care protocols and policies, as well as managers of maternal and child health programmes and policy-makers in all settings. The guideline will also be useful to tho... more

Download (347)

View PDF (932)

Inter-agency Guiding Principles on unaccompanied and separated children

ICRC, UNHCR, Wolrd Vision Save the Children UK, IRC, Unicef (2004) C1

Action on behalf of unaccompanied and separated children should be guided by principles enshrined in international standards. The validity of these principles has been confirmed by experience and lessons learnt from conflicts and natural disasters in recent years. The objective of the present public... more

Download (118)

View PDF (154)

Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019

World Health Organization (2019) C_WHO

Accountability for the global health sector strategies, 2016–2021 WHO/CDS/HIV/19.7

Download (105)

View PDF (132)

WHO Bangladesh Country Cooperation Strategy: 2020–2024

World Health Organization (WHO), Regional Office for South-East Asia (2022) C_WHO

Notable progress has also been made on other key health indicators such as reducing maternal, infant and child deaths and malnutrition, increasing immunization coverage, eliminating infectious diseases such as polio and reducing the incidence of malaria, tuberculosis and diarrhoeal diseases. But ... more

Download (393)

View PDF (674)

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended

World Health Organization (WHO) (2019) C_WHO

The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci... more

Download (283)

View PDF (315)

Children & neurodevelopmental behavioural intellectual disorders

World Health Organization (2011) C_WHO

Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization

Download (601)

View PDF (1293)

WFP South Sudan Situation Report #175, 8 May 2017

World Food Programme (2017) C1

Highlights The third corridor for delivery of humanitarian assistance from Sudan to South Sudan is open. In response to the drastic increase in humanitarian needs, WFP continues to scale up its assistance in Eastern Equatoria, Northern Bahr El Ghazal and Lakes states. Construction w... more

Download (424)

View PDF (788)

A Guide to Identifying and Documenting Best Practices in Family Planning Programmes

World Health Organization WHO, Regional Office for Africa (2017) C_WHO

Best practices” are exemplary public health practices that have achieved results, and which need to be scaled up so as to benefit more people. The expansion and institutionalization of successfully tested best practices requires strategic planning. There are several creative and constructive actio... more

Download (2071)

View PDF (2494)

WHO-WPR Emergency Response Manual

World Health Organization, Western Pacific Office (2003)

Guidelines for WHO Representatives and Country Offices in the Western Pacific Region

Download (262)

View PDF (165)

Global Antimicrobial Resistance Surveillance System (GLASS): Molecular methods

World Health Organization WHO (2019) C_WHO

Molecular methods for antimicrobial resistance (AMR)diagnostics to enhance the Global Antimicrobial Resistance Surveillance System

Download (135)

View PDF (189)

IOM Yemen: April to December 2020 Appeal

International Organization for Migration (2020) CC

The humanitarian crisis in Yemen is the worst in the world, with over 80 per cent of the population estimated to be in need of humanitarian assistance. The protracted crisis has displaced millions of Yemenis, placing pressure on host communities with limited capacity to support displaced populations... more

Download (110)

View PDF (117)

Childhood Obesity Surveillance Initiative (COSI) protocol

World Health OrganizationEurope (2016) C_WHO

The WHO Regional Office for Europe has established the Childhood Obesity Surveillance Initiative in more than half the countries in the Region for routine monitoring of the policy response to the emerging obesity epidemic. The aim of the Initiative is to measure trends in overweight and obesity in c... more

Download (100)

View PDF (124)

Childhood Obesity Surveillance Initiative (COSI) - Data collection procedures

World Health OrganizationEurope (2016) C_WHO

The WHO Regional Office for Europe has established the Childhood Obesity Surveillance Initiative in more than half thecountries in the Region for routine monitoring of the policy response to the emerging obesity epidemic. The aim of the system is to measure trends in overweight and obesity in childr... more

Download (115)

View PDF (110)

Second report on progress

World Health Organization WHO (2021) C_WHO

Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021 “The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "

Download (88)

View PDF (120)

COVID-19 new variants: Knowledge gaps and research

World Health Organization WHO (2021) C_WHO

n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants. The key objectives were to identify the critical research questions related to var... more

Download (202)

View PDF (269)

WHO Guidance: Ethics and vector-borne diseases

World Health Organization WHO (2020) C_WHO

The primary audience for this guidance is persons working directly in vector-borne disease prevention and control, including programme managers, researchers and field workers. A brief technical background is provided for the benefit of persons without expertise in vector-borne diseases; readers... more

Download (182)

View PDF (252)

Safety and quality of water used with fresh fruits and vegetables

Food and Agriculture Organization of the United Nations FAO; World Health Organization (WHO) (2021) C_WHO

During fresh fruit and vegetables (FFV) production, water is used for a variety of purposes. Even the water was conventionally treated and disinfected, it may still potentially contain human pathogens, albeit at low concentrations. A risk assessment, appropriate to the national or local production c... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Guidelines on tuberculosis infection prevention and control, 2019 update recommended

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended